Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience

Podobne zapisy

• Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
  od: Andrew J. Yee, i wsp.
  Wydane: (2025-03-01)
• P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
  od: I. Vaxman, i wsp.
  Wydane: (2022-06-01)
• PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS
  od: Tassia Cristina Decimoni, i wsp.
  Wydane: (2023-08-01)
• The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
  od: Hitomi Nakayama, i wsp.
  Wydane: (2024-09-01)
• Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
  od: Ricardo D. Parrondo, i wsp.
  Wydane: (2025-05-01)